✨ Free AI Report
TherapeuticsMD, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research TherapeuticsMD, Inc.
Company Research

TherapeuticsMD, Inc.: Business Overview, Financials & Competitive Analysis

TherapeuticsMD, Inc. scores 3/10 on the AskCyborg Cyborg Score (Weak). Distressed micro-cap royalty play dependent on partner execution with pending acquisition expected to provide exit, but standalone viability questionable absent strategic transaction completion. Company faces significant financial headwinds with negative operating income (-$4.76M) and minimal revenue ($1.76M TTM). Trading at distressed valuation with extremely limited market cap (~$14M). While the.

What is TherapeuticsMD, Inc.'s industry? TherapeuticsMD, Inc. (therapeuticsmd.com) operates in Pharmaceutical Royalties / Women's Healthcare. AskCyborg classifies TherapeuticsMD, Inc. under Pharmaceutical Royalties / Women's Healthcare in its company registry.

TherapeuticsMD is a pharmaceutical royalty company focused on women's healthcare, licensing differentiated products including prenatal vitamins (IMVEXXY, BIJUVA, ANNOVERA) through Mayne Pharma under the BocaGreenMD an...

3/ 10Weak

Cyborg Score thesis

Distressed micro-cap royalty play dependent on partner execution with pending acquisition expected to provide exit, but...

Read the full analyst-debate transcript →
Industry Pharmaceutical Royalties / Women's Healthcare
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest TherapeuticsMD, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for TherapeuticsMD, Inc.

AskCyborg analysts argue the bull and bear cases for TherapeuticsMD, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
TherapeuticsMD, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

TherapeuticsMD, Inc. Overview

Pro stress-test →

TherapeuticsMD is a pharmaceutical royalty company focused on women's healthcare, licensing differentiated products including prenatal vitamins (IMVEXXY, BIJUVA, ANNOVERA) through Mayne Pharma under the BocaGreenMD and vitaMedMD brands. The company generates revenue through exclusive licensing agreements with partners who handle commercialization and distribution.

Strategic Profile

Pro stress-test →

As a specialized royalty-based business model, TherapeuticsMD avoids traditional drug development costs while maintaining intellectual property interests in innovative women's health solutions. The company has pivoted from traditional pharmaceutical operations to a lean royalty structure, focusing on strategic partnerships to maximize shareholder value through niche market positioning.

Competitive Landscape

Pro stress-test →

TherapeuticsMD operates in women's healthcare pharma segment competing against integrated pharmaceutical companies and specialized women's health players. Primary competitive advantage lies in focused product portfolio and partnership model avoiding R&D costs. Direct competitors include women's health divisions of major pharma (Allergan, Bayer) and specialized players, though TherapeuticsMD's royalty structure differentiates positioning.

Industry Context

TherapeuticsMD, Inc. operates in Pharmaceutical Royalties / Women's Healthcare.

Key facts

Founded: 2008 · Headquarters: Boca Raton, Florida · Revenue: $1.76M · Market cap: $14.2M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on TherapeuticsMD, Inc..

  • Company underwent transformation from integrated pharma to pure-play royalty model, dramatically reducing cost structure and operational scope
  • Heavy reliance on single partnership with Mayne Pharma for three core products creates concentration risk but reduces execution burden
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2022Definitive acquisition agreement announced with EW Healthcare Partners at $10 per share for approximately $177M enterprise value
  • 2024Full year net loss from continuing operations improved to $(2.3)M vs $(7.7)M in 2023, demonstrating cost control efforts
  • +1 moreTrack every material event for TherapeuticsMD, Inc. as it happens. Explore monitoring →
Get alerted when TherapeuticsMD, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Women's Health Products PortfolioIntegrated pharma with comprehensive women's health offerings→Women's Health FranchiseLarge-scale women's healthcare and contraceptive products→Prenatal Vitamins and OTC Women's HealthPrimary commercialization partner for TXMD products→

Compare TherapeuticsMD, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

TherapeuticsMD, Inc. operates in Pharmaceutical Royalties / Women's Healthcare. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical Royalties / Women's Healthcare research →
NEW · MCP server

Ask your AI assistant about TherapeuticsMD, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare TherapeuticsMD, Inc. and its top competitor on Cyborg Score”
“What did TherapeuticsMD, Inc. do this quarter?”
“Is TherapeuticsMD, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does TherapeuticsMD, Inc. do?+
TherapeuticsMD is a pharmaceutical royalty company focused on women's healthcare, licensing differentiated products including prenatal vitamins (IMVEXXY, BIJUVA, ANNOVERA) through Mayne Pharma under the BocaGreenMD an...
What is TherapeuticsMD, Inc.'s Cyborg Score?+
TherapeuticsMD, Inc. has a Cyborg Score of 3/10 (Weak). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are TherapeuticsMD, Inc.'s main competitors?+
Named competitors include Women's Health Products Portfolio, Women's Health Franchise, Prenatal Vitamins and OTC Women's Health. The full competitive landscape is in the AskCyborg report.
How can I get the full TherapeuticsMD, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the TherapeuticsMD, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track TherapeuticsMD, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.